<article article-type="case-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mil Med</journal-id><journal-id journal-id-type="iso-abbrev">Mil Med</journal-id><journal-id journal-id-type="pmc-domain-id">3647</journal-id><journal-id journal-id-type="pmc-domain">milmed</journal-id><journal-id journal-id-type="publisher-id">milmed</journal-id><journal-title-group><journal-title>Military Medicine</journal-title></journal-title-group><issn pub-type="ppub">0026-4075</issn><issn pub-type="epub">1930-613X</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12826854</article-id><article-id pub-id-type="pmcid-ver">PMC12826854.1</article-id><article-id pub-id-type="pmcaid">12826854</article-id><article-id pub-id-type="pmcaiid">12826854</article-id><article-id pub-id-type="pmid">40338652</article-id><article-id pub-id-type="doi">10.1093/milmed/usaf175</article-id><article-id pub-id-type="publisher-id">usaf175</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group></article-categories><title-group><article-title>Drug-Induced Liver Injury with Novel Fat Burner AlbutarexV2 in an Active Duty Sailor</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-3636-831X</contrib-id><name name-style="western"><surname>Lilley</surname><given-names initials="LJ">Lt Jessica</given-names></name><degrees>MD</degrees><aff>
<institution>Internal Medicine Residency, Naval Medical Center San Diego</institution>, San Diego, CA 92134, <country country="US">USA</country></aff><xref ref-type="corresp" rid="COR0001"/><xref ref-type="author-notes" rid="FT0001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-2654-0040</contrib-id><name name-style="western"><surname>Wiseman</surname><given-names initials="M">Melanie</given-names><prefix>LCDR</prefix></name><degrees>MD</degrees><aff>
<institution content-type="department">Division of Gastroenterology, Department of Medicine, Naval Medical Center San Diego</institution>, San Diego, CA 92134, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sadowski</surname><given-names initials="B">Brett</given-names><prefix>LCDR</prefix></name><degrees>MD</degrees><aff>
<institution content-type="department">Division of Gastroenterology, Department of Medicine, Naval Medical Center San Diego</institution>, San Diego, CA 92134, <country country="US">USA</country></aff></contrib></contrib-group><author-notes><corresp id="COR0001">Corresponding author: Jessica L. Lilley, MD, USA (<email xlink:href="jessica.lilley110@gmail.com" xmlns:xlink="http://www.w3.org/1999/xlink">jessica.lilley110@gmail.com</email>).</corresp><fn id="FT0001"><p>The views expressed in this material are those of the authors, and do not reflect the official policy or position of the U.S. Government, the Department of Defense, or the Department of the Army.</p><p>Poster presentation at ACG Vancouver Oct 2023.</p></fn></author-notes><pub-date pub-type="collection"><season>Jan-Feb</season><year>2026</year></pub-date><pub-date iso-8601-date="2025-05-08" pub-type="epub"><day>08</day><month>5</month><year>2025</year></pub-date><volume>191</volume><issue>1-2</issue><issue-id pub-id-type="pmc-issue-id">505878</issue-id><fpage>e433</fpage><lpage>e435</lpage><history><date date-type="received"><day>20</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>10</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2025</year></date><date date-type="editorial-decision"><day>21</day><month>3</month><year>2025</year></date><date date-type="corrected-typeset"><day>08</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>23</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-23 16:25:14.407"><day>23</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© Oxford University Press 2025.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="usaf175.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri xlink:href="usaf175.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>ABSTRACT</title><p>Drug-induced liver injury ranges from asymptomatic to liver failure with supplements becoming an increasingly recognized cause. This case highlights the unique supplement, AlbutarexV2, and the severe cholestatic liver injury it induced with resolution occurring in six months. With steadily increasing obesity rates and supplement use, weight-loss supplements are gaining popularity with various claims of increasing energy expenditure or metabolic rate. Recognition of adverse effects from these therapies is critical to aid in identification and cessation of the agent and helping ban harmful supplements. This case demonstrates the danger of “fat-burners” and delineates the protracted and prolonged liver injury of AlbutarexV2.</p></abstract><counts><page-count count="3"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Drug-induced liver injury (DILI) ranges from asymptomatic transaminitis to acute liver failure and is classified by clinical presentation, mechanism of hepatotoxicity, and histological appearance of liver biopsy.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> For the clinical presentation, DILI is defined by elevation in liver chemistries, but it can range from a hepatocellular pattern to a cholestatic pattern.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Hepatocellular injury has 3 times the upper limit of normal (ULN) elevation of transaminases, whereas in cholestatic injury alkaline phosphatase (ALP) is three times the ULN.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Mixed pattern of injury has elevations in both transaminases and ALP.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> The diagnostic evaluation includes duration of exposure, symptoms present, sufficient exclusionary tests (viral serology, imaging, autoimmune work-up), and liver biopsy if necessary.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> Because of underreporting and comprehensive diagnostic criteria, DILI incidence is difficult to truly ascertain, but the incidence has been reported between 13.9 and 19.1 cases per 100,000 people per year.<sup><xref ref-type="bibr" rid="R3">3</xref></sup></p><p>Multiple risk factors have been implicated for development of DILI including female sex, higher drug doses, longer duration of use, and older age.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> The higher incidence in women is theorized to be due to hormonal interactions while the risk factor of older age is thought to be because of increased prescription drug use allowing for more interactions to result in adverse events.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> The U.S. Dietary Supplement Health and Education Act outlined the legal definition and labeling for dietary supplements and placed supplements under the regulation of the Food and Drug Administration (FDA).<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Although the FDA has issued formal guidance on “Good Manufacturing Practice” to attempt to ensure proper preparation and labeling of supplements, the sheer volume of supplements produced leads to many of these supplements and their unsupported health benefit claims never receiving any oversight or regulation.<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Supplements are not required to provide information on the bioactivity or provide their specific formulations instead listing them as “proprietary blends.”<sup><xref ref-type="bibr" rid="R4">4</xref></sup></p></sec><sec id="s2"><title>CASE REPORT</title><p>An overweight 22-year-old male active duty sailor presented with 7 days of painless jaundice and pruritus found to have a severe mixed and predominantly cholestatic liver injury in the setting of fat burner supplementation use (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). One week before the development of symptoms, the patient started Albutarex V2 to meet required weight standards for the military and continued usage through the jaundice and pruritus (<xref ref-type="table" rid="T2"><bold>Table 2</bold></xref>). The patient had not received antimicrobials or any other prescription drugs associated with DILI before his initial presentation. After discontinuing the supplement, the patient’s labs peaked 3 months after with AST 70 (Reference: 12-39), ALT 65 (Reference: 17-63), ALP 326 (Reference: 40-129), and bilirubin 41.66 (Reference: 0.15-1) with an R factor 0.6. Full resolution of the patient’s liver chemistries occurred at 6 months after supplementation cessation (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). A broad work-up for alternative causes of liver injury including viral hepatitis, autoimmune hepatitis, primary biliary cholangitis (PBC), Wilson’s disease, syphilis, and HIV was negative (<xref ref-type="table" rid="T3"><bold>Table 3</bold></xref>). Magnetic resonance cholangiopancreatography (MRCP) showed normal hepatic morphology with periportal edema and no evidence of any infiltrative process and normal bile ducts. While the patient had a positive antinuclear antibody (ANA), he also had a negative antismooth muscle antibody and total immunoglobulin G. It would also be atypical for autoimmune hepatitis to have profound elevation in bilirubin and a mild aminotransferase elevation pattern. Given the patient’s positive AMA, he was empirically trialed on Ursodiol to relieve his intractable pruritus. However, based on the patient’s demographic and unremarkable MRCP making PBC unlikely, Ursodiol was discontinued when it did not alleviate the patient’s pruritus. Given the progressive liver injury, a liver biopsy was obtained and interpreted by a pathologist, which revealed severe bland canalicular cholestasis without evidence of autoimmune hepatitis nor infiltrative process, consistent with DILI (<xref ref-type="sec" rid="s4">Supplemental Figure 1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Trends in Laboratory Data Over Time.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" colspan="1" rowspan="1" valign="bottom"> </td><th align="left" colspan="1" rowspan="1" valign="bottom">Day 0</th><th align="left" colspan="1" rowspan="1" valign="bottom">Day 1</th><th align="left" colspan="1" rowspan="1" valign="bottom">Day 2</th><th align="left" colspan="1" rowspan="1" valign="bottom">Day 10</th><th align="left" colspan="1" rowspan="1" valign="bottom">Day 23</th><th align="left" colspan="1" rowspan="1" valign="bottom">Day 25</th><th align="left" colspan="1" rowspan="1" valign="bottom">Day 104</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AST, U/L<break/>(Reference: 12–39)</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">66</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">33</td></tr><tr><td align="left" colspan="1" rowspan="1">ALT, U/L<break/>(Reference: 17–63)</td><td align="left" colspan="1" rowspan="1">137</td><td align="left" colspan="1" rowspan="1">110</td><td align="left" colspan="1" rowspan="1">101</td><td align="left" colspan="1" rowspan="1">76</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">42</td></tr><tr><td align="left" colspan="1" rowspan="1">ALP, U/L<break/>(Reference: 40–129)</td><td align="left" colspan="1" rowspan="1">186</td><td align="left" colspan="1" rowspan="1">170</td><td align="left" colspan="1" rowspan="1">178</td><td align="left" colspan="1" rowspan="1">243</td><td align="left" colspan="1" rowspan="1">326</td><td align="left" colspan="1" rowspan="1">254</td><td align="left" colspan="1" rowspan="1">71</td></tr><tr><td align="left" colspan="1" rowspan="1">Bilirubin, Total, mg/dL<break/>(Reference: 0.15–1)</td><td align="left" colspan="1" rowspan="1">17.24</td><td align="left" colspan="1" rowspan="1">15.47</td><td align="left" colspan="1" rowspan="1">17.86</td><td align="left" colspan="1" rowspan="1">34.68</td><td align="left" colspan="1" rowspan="1">41.66</td><td align="left" colspan="1" rowspan="1">36.94</td><td align="left" colspan="1" rowspan="1">0.87</td></tr><tr><td align="left" colspan="1" rowspan="1">Bilirubin, Direct mg/dL<break/>(Reference: 0.2–0.3)</td><td align="left" colspan="1" rowspan="1">12.0</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">12.3</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">41.5</td><td align="left" colspan="1" rowspan="1">24.9</td><td align="left" colspan="1" rowspan="1">Not obtained</td></tr><tr><td align="left" colspan="1" rowspan="1">PT, s<break/>(Reference: 12–15)</td><td align="left" colspan="1" rowspan="1">12.8</td><td align="left" colspan="1" rowspan="1">13.4</td><td align="left" colspan="1" rowspan="1">13.4</td><td align="left" colspan="1" rowspan="1">13.9</td><td align="left" colspan="1" rowspan="1">16.6</td><td align="left" colspan="1" rowspan="1">16.7</td><td align="left" colspan="1" rowspan="1">13.6</td></tr><tr><td align="left" colspan="1" rowspan="1">INR<break/>(Reference: 0.8–1.2)</td><td align="left" colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Eosinophils, %<break/>(Reference: 0–6)</td><td align="left" colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">3.8</td><td align="left" colspan="1" rowspan="1">3.8</td><td align="left" colspan="1" rowspan="1">3.8</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2.9</td><td align="left" colspan="1" rowspan="1">2.1</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Table of ingredients from Fat Burner AlbutarexV2.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><tbody><tr><td align="left" colspan="1" rowspan="1">Energy</td><td align="left" colspan="1" rowspan="1">0 kj</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein</td><td align="left" colspan="1" rowspan="1">0 g</td></tr><tr><td align="left" colspan="1" rowspan="1">Fat, Total</td><td align="left" colspan="1" rowspan="1">0 g</td></tr><tr><td align="left" colspan="1" rowspan="1">Carbohydrate Total</td><td align="left" colspan="1" rowspan="1">0 g</td></tr><tr><td align="left" colspan="1" rowspan="1">Sugar</td><td align="left" colspan="1" rowspan="1">0 g</td></tr><tr><td align="left" colspan="1" rowspan="1">Sodium</td><td align="left" colspan="1" rowspan="1">0 mg</td></tr><tr><td align="left" colspan="1" rowspan="1">Albutarex V2 Super Shred Complex</td><td align="left" colspan="1" rowspan="1">Caffeine (300 mg), Huperzine A 1%, Piperine, Taurine, N-Acetyl-L-Tyrosine, Theobromine, Theanine, Hordenine HCL, LeanGBB, 6-Paradol, Acetyl-<sc>l</sc>-Carnitine, African Mango (Seed) 10:1 Extract, Garcinia, Cambogia Extract, Coleus Forskolin (Root) Std to 20% Forskolin</td></tr><tr><td align="left" colspan="1" rowspan="1">Other ingredients</td><td align="left" colspan="1" rowspan="1">Contains Maltodextrin, Citric Acid, Natural and Artificial Flavors, Sucralose, FD&amp;C Red #40</td></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Additional Work-up Performed for Acute Liver Injury.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><tbody><tr><td align="left" colspan="1" rowspan="1">Hep A IgM antibody</td><td align="left" colspan="1" rowspan="1">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1">Hep A antibody</td><td align="left" colspan="1" rowspan="1">Reactive</td></tr><tr><td align="left" colspan="1" rowspan="1">HBsAg</td><td align="left" colspan="1" rowspan="1">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1">Hep B surface antibody</td><td align="left" colspan="1" rowspan="1">Reactive</td></tr><tr><td align="left" colspan="1" rowspan="1">Hep B core antibody</td><td align="left" colspan="1" rowspan="1">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1">IgM anti-HBc</td><td align="left" colspan="1" rowspan="1">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1">Hep C antibody</td><td align="left" colspan="1" rowspan="1">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1">HCV RNA</td><td align="left" colspan="1" rowspan="1">Note detected</td></tr><tr><td align="left" colspan="1" rowspan="1">Hep D virus</td><td align="left" colspan="1" rowspan="1">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1">Hep E virus</td><td align="left" colspan="1" rowspan="1">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1">EBV IgM, U/mL</td><td align="left" colspan="1" rowspan="1">&lt; 36</td></tr><tr><td align="left" colspan="1" rowspan="1">EBV DNA quantitative PCR</td><td align="left" colspan="1" rowspan="1">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1">CMV Ab IgM, U/mL</td><td align="left" colspan="1" rowspan="1">&lt;30.0</td></tr><tr><td align="left" colspan="1" rowspan="1">CMV PCR</td><td align="left" colspan="1" rowspan="1">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1">ANA</td><td align="left" colspan="1" rowspan="1">Positive, 1:80</td></tr><tr><td align="left" colspan="1" rowspan="1">Smooth muscle antibody (Units)</td><td align="left" colspan="1" rowspan="1">8</td></tr><tr><td align="left" colspan="1" rowspan="1">Ceruloplasmin, mg/dL</td><td align="left" colspan="1" rowspan="1">27</td></tr><tr><td align="left" colspan="1" rowspan="1">Acetaminophen level, mg/dL</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">Salicylate level, mg/dL</td><td align="left" colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td align="left" colspan="1" rowspan="1">HIV 1/2 AG/AB</td><td align="left" colspan="1" rowspan="1">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1">Rapid plasma reagin</td><td align="left" colspan="1" rowspan="1">Non-reactive</td></tr><tr><td align="left" colspan="1" rowspan="1">IgG subclass, 4 mg/dL<break/>(Reference: 2.4–121)</td><td align="left" colspan="1" rowspan="1">110</td></tr><tr><td align="left" colspan="1" rowspan="1">IgG total mg/dL<break/>(Reference: 600–1,600)</td><td align="left" colspan="1" rowspan="1">1,181</td></tr><tr><td align="left" colspan="1" rowspan="1">Mitochondrial antibody units</td><td align="left" colspan="1" rowspan="1">37.1 and 27.2 on repeat</td></tr></tbody></table></table-wrap></sec><sec id="s3"><title>DISCUSSION</title><p>We report the case of a 22-year-old male active duty sailor who developed a severe, predominately cholestatic liver injury following the use of a fat burner supplement to meet military weight standards. Using the Naranjo Adverse Drug Reaction Probability Scale, this case has a score of 7 indicating that the presentation is probably consistent with a drug reaction. This highlights the concerns of the usage of similar supplements for weight loss as independent to age, geographic location, ethnicity, or socioeconomic status, obesity rates are increasing exponentially with nearly one-third of the world population being classified as obese or overweight.<sup><xref ref-type="bibr" rid="R5">5</xref></sup> While the global rise in obesity is a complex health issue with multifaceted causes including sedentary lifestyles, diets, and genetic factors, it poses a unique and significant public health challenge.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> Not only does obesity increase the risk for chronic diseases, the new quick-fix from weight-loss supplement use has begun to directly impact health care with supplement-associated injuries. During 2017-2018, 57.6% of adults in the United States had used a dietary supplement in the past month with prevalence increasing with age and among women.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> With steadily increasing obesity rates and exponentially increasing dietary supplement use, loosely regulated therapies aimed at weight loss are more commonly utilized. Weight loss supplements or “fat burners” are typically marketed with claims of increasing energy expenditure by increasing the resting metabolic rate to lead to weight loss.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> According to the National Institute of Health Office of Dietary Supplements, 15% of U.S. adults have used a weight-loss dietary supplement at some point with an annual revenue of almost $2.1 billion dollars and increasing. Although many consumers view herbal dietary supplements as a holistic alternative to achieving improved health and weight loss, the supplements have a wide variety of quality and purity with limited proven safety or efficacy that can lead to liver toxicity in susceptible individuals.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Recognition of the potential adverse effects of these therapies is critical for clinicians since identification and cessation of the offending agent is the most important step in management. Case reports regarding specific supplement-related injuries are imperative to delineate the timeline of injuries and to aid in their removal from the marketplace. Albutarex V2’s supplement facts do not show dosages of their “shred complex” and instead list the components of their proprietary blend, making it difficult to discern what component was the likely catalyst to the patient’s presentation (<xref ref-type="table" rid="T3"><bold>Table 3</bold></xref>). Although some of the proprietary blend components have been shown to cause liver toxicity in mice, such as piperine and coleus forskolin, there are limited reports for all components of the blend in humans or even in vivo studies.<sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup> Because of the inability to ascertain what component of the blend caused the DILI, the safest recommendation is to remove the supplement altogether. This case demonstrates the danger of easily accessible “fat burners” and delineates the protracted and prolonged nature of the cholestatic liver injury associated with the particular supplement, Albutarex V2.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1" orientation="portrait" position="float"><label>usaf175_Supplementary_Data</label><media orientation="portrait" position="float" xlink:href="usaf175_supplementary_data.zip" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material></sec></body><back><ack id="ack1"><title>ACKNOWLEDGMENTS</title><p>None declared.</p></ack><sec id="s4"><title>SUPPLEMENTARY MATERIAL</title><p>
<xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref> is available at <italic toggle="yes">Military Medicine</italic> online.</p></sec><sec id="s5"><title>FUNDING</title><p>None declared.</p></sec><sec id="s6" sec-type="COI-statement"><title>CONFLICT OF INTEREST STATEMENT</title><p>None declared.</p></sec><sec id="s7" sec-type="data-availability"><title>DATA AVAILABILITY</title><p>The data that support the findings of this study are available on request from the corresponding author. All data are freely accessible.</p></sec><sec id="s8"><title>INSTITUTIONAL REVIEW BOARD (HUMAN SUBJECTS)</title><p>Not applicable.</p></sec><sec id="s9"><title>INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC)</title><p>Not applicable</p></sec><sec id="s10"><title>INSTITUTIONAL CLEARANCE</title><p>Institutional clearance approved.</p></sec><sec id="s11"><title>INDIVIDUAL AUTHOR CONTRIBUTION STATEMENT</title><p>J.L., MD: Initial research and initial writing of the manuscript. M.W., MD: Editing and revision of manuscript. B.S., MD: Editing and revision of manuscript and primary patient care.</p></sec><ref-list id="ref1"><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Teschke</surname>  <given-names>R</given-names></string-name>
</person-group>. <article-title>Idiosyncratic DILI: Analysis of 46,266 Cases assessed for causality by RUCAM and published From 2014 to Early 2019</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2019</year>;<volume>10</volume>:<fpage>1663</fpage>–<lpage>9812</lpage>.doi: <pub-id pub-id-type="doi">10.3389/fphar.2019.00730</pub-id><pub-id pub-id-type="pmid">31396080</pub-id>
<pub-id pub-id-type="pmcid">PMC6664244</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Alempijevic</surname>  <given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zec</surname>  <given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Milosavljevic</surname>  <given-names>T</given-names></string-name></person-group>. <article-title>Drug-induced liver injury: do we know everything?</article-title>  <source><italic toggle="yes">World J Hepatol</italic></source>. <year>2017</year>;<volume>9</volume>(<issue>10</issue>):<page-range>491</page-range>.doi: <pub-id pub-id-type="doi">10.4254/wjh.v9.i10.491</pub-id><pub-id pub-id-type="pmcid">PMC5387361</pub-id><pub-id pub-id-type="pmid">28443154</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Katarey</surname>  <given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname>  <given-names>S</given-names></string-name></person-group>. <article-title>Drug-induced liver injury</article-title>. <source><italic toggle="yes">Clin Med</italic></source>. <year>2016</year>;<volume>16</volume>(<issue>Suppl_6</issue>):<fpage>s104</fpage>–<lpage>9</lpage>.doi: <pub-id pub-id-type="doi">10.7861/clinmedicine.16-6-s104</pub-id><pub-id pub-id-type="pmcid">PMC6329561</pub-id><pub-id pub-id-type="pmid">27956449</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Bailey</surname>  <given-names>RL</given-names></string-name>
</person-group>. <article-title>Current regulatory guidelines and resources to support research of dietary supplements in the United States</article-title>. <source><italic toggle="yes">Crit Rev Food Sci Nutr</italic></source>. <year>2020</year>;<volume>60</volume>(<issue>2</issue>):<fpage>298</fpage>–<lpage>309</lpage>.doi: <pub-id pub-id-type="doi">10.1080/10408398.2018.1524364</pub-id><pub-id pub-id-type="pmid">30421981</pub-id>
<pub-id pub-id-type="pmcid">PMC6513729</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Chooi</surname>  <given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname>  <given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Magkos</surname>  <given-names>F</given-names></string-name></person-group>. <article-title>The epidemiology of obesity</article-title>. <source><italic toggle="yes">Metabolism</italic></source>. <year>2019</year>;<volume>92</volume>(<issue>92</issue>):<fpage>6</fpage>–<lpage>10</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.metabol.2018.09.005</pub-id><pub-id pub-id-type="pmid">30253139</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Omer</surname>  <given-names>T</given-names></string-name>
</person-group>. <article-title>The causes of obesity: an in-depth review</article-title>. <source><italic toggle="yes">Adv Obesity, Weight Manag Control</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>4</issue>):<fpage>90</fpage>–<lpage>4</lpage>.doi: <pub-id pub-id-type="doi">10.15406/aowmc.2020.10.00312</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Mishra</surname>  <given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stierman</surname>  <given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gahche</surname>  <given-names>J</given-names></string-name></person-group>  <year>2021</year>  <article-title>Data brief 399: dietary supplement use among adults: United States, 2017–2018</article-title> Published online February 26doi: <pub-id pub-id-type="doi">10.15620/cdc:101131</pub-id><pub-id pub-id-type="pmid">33663653</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Ferreira</surname>  <given-names>GDSA</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname>  <given-names>ALC</given-names></string-name>, <string-name name-style="western"><surname>Trevizoli</surname>  <given-names>NDC</given-names></string-name></person-group>  <etal>et al</etal>. <article-title>Acute liver failure caused by use of fat burner: a case report</article-title>. <source><italic toggle="yes">Transplant Proc</italic></source>. <year>2020</year>;<volume>52</volume>(<issue>5</issue>):<fpage>1409</fpage>–<lpage>12</lpage>.doi: <pub-id pub-id-type="doi">10.1016/j.transproceed.2020.01.072</pub-id><pub-id pub-id-type="pmid">32192741</pub-id>
</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Peacock</surname>  <given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Badea</surname>  <given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname>  <given-names>F</given-names></string-name></person-group>, <etal>et al.</etal>  <article-title>Herbal supplements in the print media: communicating benefits and risks</article-title>. <source><italic toggle="yes">BMC Complement Altern Med</italic></source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<page-range>196</page-range>.doi: <pub-id pub-id-type="doi">10.1186/s12906-019-2602-9</pub-id><pub-id pub-id-type="pmcid">PMC6679444</pub-id><pub-id pub-id-type="pmid">31375101</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Adachi</surname>  <given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kumagai</surname>  <given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hosho</surname>  <given-names>K</given-names></string-name></person-group>, <etal>et al.</etal>  <article-title>Exploring acute liver damage: slimming health foods and CYP3A4 induction</article-title>. <source><italic toggle="yes">Yonago Acta Med</italic></source>. <year>2024</year>;<volume>67</volume>(<issue>2</issue>):<fpage>124</fpage>–<lpage>34</lpage>.doi: <pub-id pub-id-type="doi">10.33160/yam.2024.05.004</pub-id><pub-id pub-id-type="pmid">38803590</pub-id>
<pub-id pub-id-type="pmcid">PMC11128086</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Rao</surname>  <given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Kolla</surname>  <given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Elshaari</surname>  <given-names>F</given-names></string-name></person-group>, <etal>et al.</etal>  <article-title>Effect of piperine on liver function of CF-1 albino mice</article-title>. <source><italic toggle="yes">Infect Disord Drug Targets</italic></source>. <year>2015</year>;<volume>15</volume>(<issue>2</issue>):<fpage>131</fpage>–<lpage>4</lpage>.doi: <pub-id pub-id-type="doi">10.2174/1871526515666150724114616</pub-id><pub-id pub-id-type="pmid">26205799</pub-id>
</mixed-citation></ref></ref-list></back></article>